Developing first-in-class cardiovascular biopharmaceuticals that target natural repair pathways.

Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Product candidate JVS-100 is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. This therapeutic approach is based on research originating at the Cleveland Clinic. Juventas is currently completing a Phase 2b study in patients with advanced peripheral artery disease.